Publication/Registration Details |
(1) 2020/47 Gaz on 2020-12-03 |
Publication/Registration Details |
(1) 2020/42 Gaz on 2020-10-29 |
|
Goods & Services Limitation Details
|
Description
Class 05 -
Pharmaceutical agents affecting metabolism; pharmaceutical
preparations for treating metabolic disorders;
pharmaceutical preparations and compositions for the
treatment and prevention of cancer; pharmaceutical products
for the treatment of cancer; chemical preparations for
pharmaceutical purposes; biotechnological preparations for
medical purposes; drugs for medical purposes; antibodies for
medical purposes; pharmaceutical compositions; medicines for
human purposes; nutritional additives for therapeutic
purposes; therapeutic drugs and agents; anti-cancer
preparations.
|
Publication/Registration Details |
(1) 2020/39 Gaz on 2020-10-08 |
|
Goods & Services Limitation Details
|
Description
Class 05 -
Pharmaceutical agents affecting metabolism; pharmaceutical
preparations for treating metabolic disorders;
pharmaceutical preparations and compositions for the
treatment and prevention of cancer; pharmaceutical products
for the treatment of cancer; chemical preparations for
pharmaceutical purposes, namely, for the treatment of viral,
metabolic, endocrine, musculoskeletal, cardiovascular,
cardiopulmonary, genitourinary, sexual dysfunction,
oncological, hepatological, ophthalmic, respiratory,
neurological, gastrointestinal, hormonal, dermatological,
psychiatric and immune system related diseases and
disorders; biotechnological preparations for medical
purposes, namely, for the treatment of oncological,
metabolic and ophthalmic diseases and disorders; drugs for
medical purposes, namely, for treating cancer; drugs for
medical purposes, namely, for treating diabetes; drugs for
medical purposes, namely, for treating ocular disease;
antibodies for medical purposes, namely, for the treatment
of oncological, metabolic and ophthalmic diseases and
disorders; pharmaceutical compositions for the treatment of
oncological, metabolic and ophthalmic diseases and
disorders; medicines for human purposes for the treatment of
oncological, metabolic and ophthalmic diseases and
disorders; nutraceuticals for therapeutic purposes for the
treatment of cancer; nutraceuticals for therapeutic purposes
for the treatment of diabetes; therapeutic drugs and agents,
namely, antibody drug conjugate comprising antibody and
chemical compound attached for the treatment of oncological,
metabolic and ophthalmic diseases and disorders; anti-cancer
preparations.
Class 42 -
Research and development of vaccines and medicines;
biotechnology research; biological research; crude medicines
research; scientific research for medical purposes in the
field of cancerous diseases; research on the subject of
pharmaceuticals; medical research; clinical research in the
field of oncology, metabolic disease and ophthalmology.
|
Publication/Registration Details |
(1) 2020/38 Gaz on 2020-10-01 |
Publication/Registration Details |
(1) 2020/3 Gaz on 2020-01-30 |
Publication/Registration Details |
(1) 2019/51 Gaz on 2020-01-02 |
|
Goods & Services Limitation Details
|
Description
Class 05 -
Pharmaceutical agents affecting metabolism; pharmaceutical
preparations for treating metabolic disorders,
pharmaceutical preparations and compositions for the
treatment and prevention of cancer; pharmaceutical products
for the treatment of cancer; chemical preparations for
pharmaceutical purposes; biotechnological preparations for
medical purposes; drugs for medical purposes; antibodies for
medical purposes; pharmaceutical compositions; medicines for
human purposes; nutraceuticals for therapeutic purposes;
therapeutic drugs and agents; anti-cancer preparations; none
of the above mentioned products being related to
extracorporeal blood treatment or renal insufficiency.
Class 42 -
Research and development of vaccines and medicines;
biotechnology research; biological research; crude medicines
research; scientific research for medical purposes in the
field of cancerous diseases; research on the subject of
pharmaceuticals; medical research; clinical research; none
of the above mentioned services being related to
extracorporeal blood treatment or renal insufficiency.
|
Publication/Registration Details |
(1) 2019/44 Gaz on 2019-11-14 |
Publication/Registration Details |
(1) 2019/39 Gaz on 2019-10-10 |
Publication/Registration Details |
(1) 2019/30 Gaz on 2019-08-08 |
|
Designated Country Details
|
(1) CN under Protocol
(2) EM under Protocol
(3) JP under Protocol
(4) US under Protocol
|